Our work further underscores the importance of molecular profiling in HER2-amplified CRC, specifically highlighting how it is critical to not only determine HER2 status but also evaluate for RAS/RAF/PIK3CA mutations using next-generation molecular profiling. The gene discussed is ERBB2; the disease is colorectal carcinoma.